| Abstract | Eleven consecutive male patients with operable Stage II (n = 7) or III (n = 4) breast cancer were treated with adjuvant chemotherapy after local therapy. Adjuvant therapy consisted of 5-fluorouracil, doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) in ten patients and cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in one patient. At a median follow-up time of 52 months, four patients experienced a relapse and seven patients were disease-free. Of those with recurrent disease, one patient died of metastatic breast cancer. These limited data suggest that adjuvant therapy reduced the risk of recurrence and favorably influenced the survival in this patient population. Adjuvant therapy should be considered in male patients with primary breast cancer. |
| Authors | H Z Patel 2nd, A U Buzdar, G N Hortobagyi
(Affiliation: Department of Medical Oncology (Medical Breast Service), University of M.D. Anderson Cancer Center, Houston, Texas.)
|
| Journal | Cancer
(Cancer)
Vol. 64
Issue 8
Pg. 1583-5
(Oct 15 1989)
ISSN: 0008-543X UNITED STATES |
| PMID | 2676137
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
- CAF protocol
- CMF protocol
- Tamoxifen
- Cisplatin
- Doxorubicin
- Cyclophosphamide
- Fluorouracil
- Methotrexate
|
| Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology, surgery)
- Cisplatin
(administration & dosage)
- Clinical Trials as Topic
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Fluorouracil
(administration & dosage)
- Humans
- Male
- Mastectomy, Modified Radical
- Mastectomy, Radical
- Methotrexate
(administration & dosage)
- Middle Aged
- Neoplasm Metastasis
- Tamoxifen
(administration & dosage)
|
